Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Wednesday, November 6th,Zacks Dividends reports. Stockholders of record on Friday, December 13th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Monday, December 30th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Friday, December 13th.

Gilead Sciences has raised its dividend by an average of 3.3% per year over the last three years. Gilead Sciences has a payout ratio of 42.4% indicating that its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $7.28 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 42.3%.

Gilead Sciences Stock Down 1.6 %

Shares of GILD traded down $1.60 during midday trading on Friday, reaching $96.30. The stock had a trading volume of 2,385,501 shares, compared to its average volume of 7,024,102. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $98.32. The company’s fifty day simple moving average is $84.58 and its two-hundred day simple moving average is $74.67. The company has a market cap of $119.89 billion, a price-to-earnings ratio of 118.29, a PEG ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the business earned $2.29 EPS. The company’s revenue was up 7.0% on a year-over-year basis. Equities research analysts expect that Gilead Sciences will post 3.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Oppenheimer raised their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a “sector perform” rating in a research note on Thursday. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday. Twelve investment analysts have rated the stock with a hold rating, ten have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $90.71.

Insider Activity

In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,437 shares of company stock valued at $5,374,825 over the last quarter. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.